Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.

ABSTRACT:

Background

How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood.

Methods

We analyzed pre- and post-treatment samples from 60 patients using the NanoString PanCancer IO360™ assay to measure the expression of 750 immune-related genes corresponding to 14 immune cell types and various immune functions, and assessed TIL counts and PD-L1 protein expression by immunohistochemistry. Treatment associated changes in gene expression levels were compared using t-test with Bonferroni correction. TIL count, PD-L1 protein and immune metagenes were compared using Wilcoxon test. Baseline immune markers were correlated with pathologic complete response (pCR) using estrogen receptor and treatment arm adjusted logistic regressio

SUBMITTER: Li X 

PROVIDER: S-EPMC6457012 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature